A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS).

Trial Profile

A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 30 May 2014 Planned End Date changed from 1 Oct 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 23 Nov 2011 Planned patient no changed from 225 to 150 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top